No Record Found
No Record Found
Sector
PharmaceuticalsOpen
₹65Prev. Close
₹65.01Turnover(Lac.)
₹42.52Day's High
₹71.5Day's Low
₹64.7452 Week's High
₹113.552 Week's Low
₹38.33Book Value
₹-75.68Face Value
₹10Mkt Cap (₹ Cr.)
144.78P/E
0EPS
0Divi. Yield
0No Record Found
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Equity Capital | 21.56 | 21.56 | 21.56 | 21.56 |
Preference Capital | 130 | 130 | 130 | 130 |
Reserves | -167.8 | -140.78 | -121.02 | -96.65 |
Net Worth | -16.24 | 10.78 | 30.54 | 54.91 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 53.7 | 33.41 | 33.77 | 3.25 |
yoy growth (%) | 60.72 | -1.08 | 937.63 | 152.43 |
Raw materials | -25.94 | -15.85 | -12.7 | -0.92 |
As % of sales | 48.31 | 47.46 | 37.61 | 28.35 |
Employee costs | -15.82 | -15.08 | -11.48 | -5.62 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | -28.35 | -28.87 | -16.61 | -15.64 |
Depreciation | -5.12 | -4.67 | -4.14 | -4.23 |
Tax paid | 0 | 0 | 0 | 0 |
Working capital | 7.39 | -3.08 | -6.51 | 0.9 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 60.72 | -1.08 | 937.63 | 152.43 |
Op profit growth | -5.65 | 148.34 | -6.22 | -35.49 |
EBIT growth | -3.76 | 100.46 | -5.86 | -23.33 |
Net profit growth | -1.77 | 61.97 | 11.06 | -1.66 |
No Record Found
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,782.2 | 142.57 | 4,27,933.39 | 608.7 | 0.9 | 4,887.27 | 93.23 |
Divis Laboratories Ltd DIVISLAB | 6,623 | 66.04 | 1,75,833.11 | 756 | 0.45 | 2,793 | 629.49 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 4,420.9 | 67.6 | 1,49,548.89 | 467 | 0.86 | 2,677 | 249.73 |
Cipla Ltd CIPLA | 1,401.3 | 32.87 | 1,13,154.89 | 384.64 | 0.93 | 3,840.92 | 423.36 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,089 | 29.67 | 1,09,568.82 | 1,722 | 0.09 | 3,564.6 | 235.25 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Non Executive Dir.
R T Ravi
Non Independent Non Executive Director / MD
Pabitra Bhattacharya
Non-Exec & Non-Independent Dir
Avinash Ravi
Independent Non Exe. Director
Popatlal M Kathariya
Independent Non Exe. Director
Dipti Shah
Independent Non Exe. Director
SATYA CHIGURUPATI
Independent Non Exe. Director
Sumanth Karlapudi
Managing Director & CEO
Manish Kumar Jain
Company Sec. & Compli. Officer
Rakesh R Kalbate
Kothapalli(V) Kasimkota(M),
Anakapalli,
Andhra Pradesh - 531031
Tel: 91-040-6680 8040
Website: http://www.krebsbiochem.com
Email: investors@krebsbiochem.com; avinashr@krebsbiochem.
Karvy Selenium Tow-B,
31&32 Financial Dist, Nanakramguda,
Hyderabad-500032
Tel: 91-40-67162222
Website: www.kfintech.com
Email: einward.ris@karvy.com
Summary
Krebs Biochemicals & Industries Limited was initially incorporated as Krebs Biochemicals Limited in 1991. The name of the Company was changed from Krebs Biochemicals Limited to Krebs Biochemicals & In...
Read More
Reports by Krebs Biochemicals & Industries Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.